Treating heart failure with preserved ejection fraction related to arterial stiffness. Can we kill two birds with one stone?

Current Vascular Pharmacology

Volumn 13, Issue 3, 2015, Pages 368-380

  Athyros, Vasilios G ^a   Pagourelias, Efstathios D ^a   Gossios, Thomas D ^b   Vasilikos, Vasilios G ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Aneamia; Arterial hypertension; Arterial stiffness; Chronic kidney disease; Diabetes mellitus; Heart failure; Preserved ejection fraction; Statins

Indexed keywords

AC 3174; ALAGEBRIUM; ATORVASTATIN; AVE 3085; CARVEDILOL; CHLORTALIDONE; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; IVABRADINE; LISINOPRIL; MATRIX METALLOPROTEINASE INHIBITOR; NEBIVOLOL; NIFEDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSUVASTATIN; S31 201; SACUBITRIL PLUS VALSARTAN; SILDENAFIL; SPIRONOLACTONE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VERAPAMIL;

ANGINA PECTORIS; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DIASTOLIC DYSFUNCTION; DRUG EFFICACY; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MULTICENTER STUDY (TOPIC); NONALCOHOLIC FATTY LIVER; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TISSUE DOPPLER IMAGING; TREATMENT RESPONSE; HEART STROKE VOLUME; VASCULAR DISEASES;

HEART FAILURE; HUMANS; STROKE VOLUME; VASCULAR DISEASES; VASCULAR STIFFNESS;

EID: 84937150563     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666141126150948     Document Type: Article

References (149)

1. [1] Oghlakian GO, Sipahi I, Fang JC. Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm? Mayo Clin Proc 2011; 86: 531-9.
2. [2] Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community. Appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202
3. [3] Oishi Y, Miyoshi H, Iuchi A, Nagase N, Ara N, Oki T. Negative impact of cardiovascular risk factors on left atrial and left ventricular function related to aortic stiffness. Circ J 2013; 77: 1490-8.
4. [4] Fischer M, Baessler A, Hense HW, et al. Prevalence of left ventricular diastolic dysfunction in the community: Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 2003; 24: 320-8.
5. [5] Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-9.
6. [6] Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease: Insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009; 54: 410-8.
7. [7] Mizuguchi Y, Oishi Y, Tanaka H, et al. Arterial stiffness is associated with left ventricular diastolic function in patients with cardiovascular risk factors: Early detection with the use of cardio-ankle vascular index and ultrasonic strain imaging. J Card Fail 2007; 13: 744-51.
8. [8] Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: Implications for systolic and diastolic reserve limitations. Circulation 2003; 107: 714-20.
9. [9] Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age-and gender-related ventricular-vascular stiffening: a community-based study. Circulation 2005; 112: 2254-62.
10. [10] Lam CS, Roger VL, Rodeheffer RJ, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007; 115: 1982-90.
11. [11] Miyoshi H, Mizuguchi Y, Oishi Y, et al. Early detection of abnormal left atrial-left ventricular-arterial coupling in preclinical patients with cardio-vascular risk factors: evaluation by twodimensional speckle-tracking echocardiography. Eur J Echocardiogr 2011; 12: 431-9.
12. [12] Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-9.
13. [13] Laurent S, Alivon M, Beaussier H, Boutouyrie P. Aortic stiffness as a tissue biomarker for predicting future cardiovascular events in asymptomatic hypertensive subjects. Ann Med 2012; 44(Suppl 1): S93-7.
14. [14] Antonini-Canterin F, Carerj S, Di Bello V, et al. Research Group of the Italian Society of Cardiovascular Echography (SIEC). Arterial stiffness and ventricular stiffness: a couple of diseases or a coupling disease? A review from the cardiologist’s point of view. Eur J Echocardiogr 2009; 10: 36-43.
15. [15] Vlachopoulos C, Alexopoulos N, Stefanadis C. Aortic stiffness: prime time for integration into clinical practice? Hellenic J Cardiol 2010; 51: 385-90.
16. [16] Athyros VG, Reklou A, Lazaridis A, Mitsiou E, Karagiannis A. Effect of metabolic risk factors clustering with or without arterial hypertension on arterial stiffness. A narrative review. Diseases 2013; 1(1): 51-72.
17. [17] Vlachopoulos C, Aznaouridis K, O’Rourke MF, et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: A systematic review and meta-analysis. Eur Heart J 2010; 31: 1865-71.
18. [18] Sassalos K, Vlachopoulos C, Alexopoulos N, Gialernios T, Aznaouridis K, Stefanadis C. The acute and chronic effect of cigarette smoking on the elastic properties of the ascending aorta in healthy male subjects. Hellenic J Cardiol 2006; 47: 263-8.
19. [19] Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106: 2085-90.
20. [20] Vlachopoulos C, O’Rourke M. Genesis of the normal and abnormal arterial pulse. Curr Probl Cardiol 2000; 25: 303-67.
21. [21] Zouein FA, de Castro Brás LE, da Costa DV, Lindsey ML, Kurdi M, Booz GW. Heart failure with preserved ejection fraction: emerging drug strategies. J Cardiovasc Pharmacol 2013; 62: 13-21
22. [22] McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-847.
23. [23] Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011; 32: 670-9.
24. [24] Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003; 362: 777-81.
25. [25] Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The Perindopril in Elderly People With Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-45.
26. [26] Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 2012; 59: 442-51.
27. [27] Sherazi S, Zar ba W. Diastolic heart failure: predictors of mortality. Cardiol J 2011; 18: 222-32.
28. [28] Zile MR, Gaasch WH, Anand IS, et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010; 121: 1393-1405.
29. [29] Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59: 998-1005.
30. [30] Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 119: e391-e479.
31. [31] SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
32. [32] CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
33. [33] Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARMAlternative trial. Lancet 2003; 362: 772-6.
34. [34] Young JB, Dunlap ME, Pfeffer MA, et al. Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004; 110: 2618-26.
35. [35] Pitt B, Zannad F, Remme WJ, et al. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.
36. [36] Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction: Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001; 15: 79-87.
37. [37] Davis BR, Kostis JB, Simpson LM, et al. ALLHAT Collaborative Research Group. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 2008; 118: 2259-67.
38. [38] Yip GW, Wang M, Wang T, et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008; 94: 573-80.
39. [39] Pfeffer MA, Swedberg K, Granger CB, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
40. [40] Massie BM, Carson PE, McMurray JJ, et al. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-67.
41. [41] Cleland JG, Tendera M, Adamus J, et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail 1999; 1: 211-7.
42. [42] Shah SJ, Heitner JF, Sweitzer NK, et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2013; 6: 184-92.
43. [43] Patel K, Fonarow GC, Kitzman DW, et al. Aldosterone Antagonists and Outcomes in Real-World Older Patients with Heart Failure and Preserved Ejection Fraction. JACC Heart Fail 2013; 1: 40-7.
44. [44] Edelmann F, Wachter R, Schmidt AG, et al. Aldo-DHF Investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013; 309: 781-91.
45. [45] Flather MD, Shibata MC, Coats AJ, et al. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-25.
46. [46] Hernandez AF, Hammill BG, O’Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009; 53: 184-92.
47. [47] Massie BM, Nelson JJ, Lukas MA, et al. COHERE Participant Physicians. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice. Am J Cardiol 2007; 99: 1263-8.
48. [48] Yamamoto K, Origasa H, Hori M; J-DHF Investigators. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013; 15: 110-8.
49. [49] Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990; 66: 981-6.
50. [50] Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263-71.
51. [51] Redfield MM, Chen HH, Borlaug BA, et al. For the RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309: 1268-77.
52. [52] Becher PM, Lindner D, Miteva K, et al. Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and beta-receptor blockade. Hypertension 2012; 59: 949-57.
53. [53] Reil JC, Hohl M, Reil GH, et al. Heart rate reduction by Ifinhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J 2013; 34(36): 2839-49.
54. [54] Lovelock JD, Monasky MM, Jeong EM, et al. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res 2012; 110: 841-50.
55. [55] Jeong EM, Monasky MM, Gu L, et al. Tetrahydrobiopterin improves diastolic dysfunction by reversing changes in myofilament properties. J Mol Cell Cardiol 2013; 56: 44-54.
56. [56] Moens AL, Ketner EA, Takimoto E, et al. Bi-modal dosedependent cardiac response to tetrahydrobiopterin in pressureoverload induced hypertrophy and heart failure. J Mol Cell Cardiol 2011; 51: 564-9.
57. [57] Westermann D, Riad A, Richter U, et al. Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. Basic Res Cardiol 2009; 104: 499-509.
58. [58] Tocchetti CG, Stanley BA, Murray CI, et al. Playing with cardiac ‘redox switches’: the ‘HNO way’ to modulate cardiac function. Antioxid Redox Signal 2011; 14: 1687-98.
59. [59] Gao WD, Murray CI, Tian Y, et al. Nitroxyl-mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function. Circ Res 2012; 111: 1002-11.
60. [60] Chiao YA, Ramirez TA, Zamilpa R, et al. Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc Res 2012; 96: 444-5.
61. [61] Lauer-Fields JL, Whitehead JK, Li S, et al. Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J Biol Chem 2008; 283: 20087-95.
62. [62] Baicu CF, Zile MR, Aurigemma GP, Gaasch WH. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation 2005; 111: 2306-12.
63. [63] Mir SA, Chatterjee A, Mitra A, et al. Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart. J Biol Chem 2012; 287: 2666-77.
64. [64] Willemsen S, Hartog JW, van Veldhuisen DJ, et al. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction. Am Heart J 2012; 164: 742-9.e3.
65. [65] Little WC, Zile MR, Kitzman DW, et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005; 11: 191-5.
66. [66] Booz GW. Putting the brakes on cardiac hypertrophy: exploiting the NO-cGMP counterregulatory system. Hypertension 2005; 45: 341-6.
67. [67] Solomon SD, Zile M, Pieske B, et al. Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387-95.
68. [68] Wilson RM, De Silva DS, Sato K, et al. Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure. Hypertension 2009; 54: 583-90.
69. [69] Wojtczak-Soska K, Pietrucha T, Sakowicz A, et al. Soluble ST2 protein in chronic heart failure is independent of traditional factors. Arch Med Sci 2013; 9: 21-6.
70. [70] Bujak M, Frangogiannis NG. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz) 2009; 57: 165-76.
71. [71] Blacher J, Safar ME. Large-artery stiffness, hypertension and cardiovascular risk in older patients. Nat Clin Pract Cardiovasc Med 2005; 2: 450-5.
72. [72] Chen CH, Nakayama M, Talbot M, et al. Verapamil acutely reduces ventricular-vascular stiffening and improves aerobic exercise performance in elderly individuals. J Am Coll Cardiol 1999; 33: 1602-9.
73. [73] Chen CH, Nakayama M, Nevo E, Fetics BJ, Maughan WL, Kass DA. Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol 1998; 32: 1221-7.
74. [74] Daemen J. Diastolic dysfunction and arterial stiffness: the chicken or the egg. Neth Heart J 2013; 21: 219-21.
75. [75] Kass DA. Ventricular Arterial Stiffening. Integrating the pathophysiology. Hypertension 2005; 46: 185-93.
76. [76] Sweitzer NK, Hetzel SJ, Skalski J, Velez M, Eggleston K, Mitchell GF. Left ventricular responses to acute changes in late systolic pressure augmentation in older adults. Am J Hypertens 2013; 26: 866-71.
77. [77] Triposkiadis FK, Skoularigis J. Prevalence and importance of comorbidities in patients with heart failure. Curr Heart Fail Rep 2012; 9: 354-62.
78. [78] Lang CC, Mancini DM. Non-cardiac comorbidities in chronic heart failure. Heart 2007; 93: 665-71.
79. [79] Triposkiadis F, Starling RC, Boudoulas H, et al. The cardiorenal syndrome in heart failure: Cardiac? Renal? Syndrome? Hear Fail Rev 2012; 17: 355-66.
80. [80] Kaila K, Haykowsky MJ, Thompson RB, Paterson DI. Heart failure with preserved ejection fraction in the elderly: scope of the problem. Heart Fail Rev 2012; 17: 555-62.
81. [81] Laurent S, Boutouyrie P. Recent advances in arterial stiffness and wave reflection in human hypertension. Hypertension 2007; 49: 1202-6.
82. [82] Kitzman DW, Rich MW. Age disparities in heart failure research. JAMA 2010; 304: 1950-1.
83. [83] Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282-9.
84. [84] Fontes-Carvalho R, Leite-Moreira A. Heart failure with preserved ejection fraction: fighting misconceptions for a new approach. Arq Bras Cardiol 2011; 96: 504-14.
85. [85] ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Eur Heart J 2008; 29: 2388-442.
86. [86] ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981-97.
87. [87] Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-98.
88. [88] Cohen RS, Karlin P, Yushak M, Mancini D, Maurer MS. The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction. Congest Heart Fail 2010; 16: 96-103.
89. [89] Bitter T, Westerheide N, Faber L, et al. Adaptive servoventilation in diastolic heart failure and Cheyne-Stokes respiration. Eur Respir J 2010; 36: 385-92.
90. [90] Yoshihisa A, Shimizu T, Owada T, et al. Adaptive servo ventilation improves cardiac dysfunction and prognosis in chronic heart failure patients with Cheyne-Stokes respiration. Int Heart J 2011; 52: 218-23.
91. [91] Bender SB, McGraw AP, Jaffe IZ, et al. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes 2013; 62: 313-9.
92. [92] D browski R, Szwed H. Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation. Cardiol J 2012; 19: 223-9.
93. [93] Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther 2012; 133: 311-23.
94. [94] Cheang WS, Wong WT, Tian XY, et al. Endothelial nitric oxide synthase enhancer reduces oxidative stress and restores endothelial function in db/db mice. Cardiovasc Res 2011; 92: 267-75.
95. [95] Johnson AW, Kinzenbaw DA, Modrick ML, et al. Small-molecule inhibitors of signal transducer and activator of transcription 3 protect against angiotensin II-induced vascular dysfunction and hypertension. Hypertension 2013; 61: 437-42.
96. [96] Teupe C, Rosak C. Diabetic cardiomyopathy and diastolic heart failure -difficulties with relaxation. Diabetes Res Clin Pract 2012; 97: 185-94.
97. [97] Maisch B, Alter P, Pankuweit S. Diabetic cardiomyopathy-fact or fiction? Herz 2011; 36: 102-15.
98. [98] Isfort M, Stevens SC, Schaffer S, Jong CJ, Wold LE. Metabolic dysfunction in diabetic cardiomyopathy. Heart Fail Rev 2014; 19(1): 35-48.
99. [99] Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583-90.
100. [100] Gitt AK, Halle M, Hanefeld M, et al. Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without? Eur J Heart Fail 2012; 14: 1389-400.
101. [101] Naka KK, Pappas K, Papathanassiou K, et al. Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study. Cardiovasc Diabetol 2010; 9: 57-65.
102. [102] Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345-51.
103. [103] Benes J, Kazdova L, Drahota Z, et al. Effect of metformin therapy on cardiac function and survival in a volume-overload model of heart failure in rats. Clin Sci (Lond) 2011; 121: 29-41.
104. [104] Aguilar D. Management of type 2 diabetes in patients with heart failure. Curr Treat Options Cardiovasc Med 2008; 10: 465-75.
105. [105] Liu Q, Anderson C, Broyde A, et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 2010; 9: 76-89.
106. [106] Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009; 15: 479-89.
107. [107] Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005; 112: 357-63.
108. [108] Foody JM, Shah R, Galusha D, Masoudi FA, Havranek EP, Krumholz HM. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 2006; 113: 1086-92.
109. [109] Roik M, Starczewska MH, Huczek Z, Kochanowski J, Opolski G. Statin therapy and mortality among patients hospitalized with heart failure and preserved left ventricular function-a preliminary report. Acta Cardiol 2008; 63: 683-92.
110. [110] Tehrani F, Morrissey R, Phan A, Chien C, Schwarz ER. Statin therapy in patients with diastolic heart failure. Clin Cardiol 2010; 33: E1-5.
111. [111] Kanaki AI, Sarafidis PA, Georgianos PI, et al. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens 2013; 26: 608-16.
112. [112] Sadat U, Howarth SP, Usman A, et al. Effect of low-and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging -a post-hoc sub group analysis of ATHEROMA (Atorvastatin Therapy: Effects On Reduction Of Macrophage Activity) Study. J Atheroscler Thromb 2013; 20: 46-56.
113. [113] Matsuo T, Iwade K, Hirata N, et al. Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia. Heart Vessels 2005; 20: 8-12.
114. [114] Wang F, Ye P, Luo L, et al. Association of serum lipids with arterial stiffness in a population-based study in Beijing. Eur J Clin Invest 2011; 41: 929-36.
115. [115] Hongo M, Kumazaki S, Izawa A, et al. Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipdemia in a primary prevention group. Circ J 2011; 75: 2660-7.
116. [116] Hongo M, Tsutsui, H, Mawatari E, et al. Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study. Circ J 2008; 72: 722-8.
117. [117] Kontopoulos AG, Athyros VG, Pehlivanidis AN, Demitriadis DS, Papageorgiou AA, Boudoulas H. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr Med Res Opin 2003; 19: 22-7.
118. [118] Igase M, Kohara K, Tabara Y, et al. Low-dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia. Menopause 2012; 19: 1294-9.
119. [119] Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Sharman JE, Coombes JS. Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial. J Atheroscler Thromb 2010; 17; 235-41.
120. [120] Orr JS, Dengo AL, Rivero JM, Davy KP. Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension 2009; 54: 763-8.
121. [121] Mukherjee S, Mukhopadhyay P, Pandit K, Chowdhury S. Atorvastatin improves arterial stiffness in normotensive normolipidaemic persons with type 2 diabetes. J Indian Med Assoc 2008; 106: 716-9.
122. [122] Haller MJ, Stein JM, Shuster JJ, et al. Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009; 22: 65-8.
123. [123] Lunder M, Jani M, Habjan S, Sabovi M. Subtherapeutic, lowdose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males-a pilot study. Atherosclerosis 2011; 215: 446-51.
124. [124] Tam LS, Li EK, Shang Q, et al. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Scand J Rheumatol 2011; 40: 411-21.
125. [125] Wang J, Xu J, Zhou C, et al. Improvement of arterial stiffness by reducing oxidative stress damage in elderly hypertensive patients after 6 months of atorvastatin therapy. J Clin Hypertens (Greenwich) 2012; 14: 245-9.
126. [126] Toyama K, Sugiyama S, Oka H, et al. Combination treatment of rosuvastatin or atorvastatin, with regular exercise improves arterial wall stiffness in patients with coronary artery disease. PLoS One 2012; 7: e41369-76.
127. [127] Jondeau G, Arnoult F, Caligiuri G, et al. Practical management of heart failure with preserved ejection fraction. A modest proposal. Arch Cardiovasc Dis 2013; 106: 345-8.
128. [128] Kjekshus J, Apetrei E, Barrios V, et al. CORONA Group Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-61.
129. [129] Tavazzi L, Maggioni AP, Marchioli R, et al. Gissi-HF Investigators Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-9.
130. [130] Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007; 115: 576-83.
131. [131] Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-8.
132. [132] Athyros VG, Karagiannis A, Mikhailidis DP. Statins and heart failure. J Am Coll Cardiol 2010; 55: 1644-5.
133. [133] Athyros VG, Karagiannis A, Katsiki N, Mikhailidis DP. Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity. Am J Cardiol 2012; 110: 763.
134. [134] Jennifer E. Ho, David D. Waters, et al, TNT Investigators. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] Study). Am J Cardiol 2012; 109: 1761-6.
135. [135] Bonsu KO, Kadirvelu A, Reidpath DD. Statins in heart failure: do we need another trial? Vasc Health Risk Manag 2013; 9: 303-19.
136. [136] Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 2012; 35: 389-95.
137. [137] Goland S, Shimoni S, Zornitzki T, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 2006; 40: 949-55.
138. [138] Huang RC, Beilin LJ, Ayonrinde O, et al. The importance of cardio-metabolic risk factors in the association between non alcoholic fatty liver disease and arterial stiffness. Hepatology 2013 May 22. [Epub ahead of print]
139. [139] Salvi P, Ruffini R, Agnoletti D, et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens 2010; 28: 1699-707.
140. [140] Athyros VG, Tziomalos K, Gossios TD, et al. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
141. [141] Bruch C, Rothenburger M, Gotzmann M, et al. Chronic kidney disease in patients with chronic heart failure--impact on intracardiac conduction, diastolic function and prognosis. Int J Cardiol 2007; 118: 375-80.
142. [142] Franssen CF, Navis G. Chronic kidney disease: RAAS blockade and diastolic heart failure in chronic kidney disease. Nat Rev Nephrol 2013; 9: 190-2.
143. [143] Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-34.
144. [144] Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004; 18: 781-8.
145. [145] Fernandez-Fresnedo G, Rodrigo E, de Francisco AL, de Castro SS, Castañeda O, Arias M. Role of pulse pressure on cardiovascular risk in chronic kidney disease patients. J Am Soc Nephrol 2006; 17(Suppl 3): S246-9.
146. [146] Tang ZH, Fang Z, Zeng F, Li Z, Zhou L. Association and interaction analysis of metabolic syndrome and serum uric acid on diastolic heart failure. J Endocrinol Invest 2013; 36(8): 579-83.
147. [147] Gotsman I, Keren A, Lotan C, Zwas DR. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J Card Fail 2012; 18: 694-701.
148. [148] Bickel C, Rupprecht H J, Blankenberg S, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002; 89: 12-17.
149. [149] Athyros VG, Elisaf M, Papageorgiou AA, et al. GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronaryheart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-99.